Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung di...
Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
About this item
Full title
Author / Creator
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
Background
The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non‐small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk of ICI‐related pneumonitis is...
Alternative Titles
Full title
Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026605
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6026605
Other Identifiers
ISSN
1759-7706
E-ISSN
1759-7714
DOI
10.1111/1759-7714.12759
